Pernix Therapeutics Holdings Inc

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)) Applauses Court’s Ruling

Pernix Therapeutics Holdings Inc (NASDAQ:PTX), has today given a statement regarding the lawsuit with Actavis Laboratories FL. According to it, the judges had given a ruling that favored them in a big way. The proposed generic version of Zohydro ER had for a long period left it in suspense and as a matter of fact a lot of speculations were made. The court ruling has cleared the air around the matter making uncertainties a matter of the past for the company. Judge Gregory M. Sleet of the United States District Court for the District of Delaware came to the conclusion that indeed the generic versions of Zohydro that had earlier on been proposed by Actavis had been out of order.

John Sedor, who is both the Chairman and CEO of Pernix said, “We are pleased with the Court’s decision as it confirms the strength and longevity of the Zohydro ER patent portfolio. Zohydro ER is a core component of our product portfolio and we look forward to driving continued growth of the franchise.”

The two patents are enlisted in FDA’S “Orange Book” which is under Zohydro ER it is Recro Gainesville LLC that made the decision to license it to Pernix.

The U.S. is a huge market for drugs and that is of course based on the large number of people in need of drugs. Pernix Therapeutics acquires, develops and commercializes prescription drugs which it sells mostly to the U.S. market. In as much as the U.S. is one of the most developed nations in the world, there are still some areas which are underserved .The company well understands the discomforts associated with therapeutic areas e.g. CNS, including pain management and neurology. Expansion plans are underway which are supposed to see to it that additional specialty segments are established. The company is very good when it comes to the promotion of its branded products to a wide range of physicians. It does that through the integrated Pernix sales force. A lot of changes are being implemented and it is hoped they will do much towards helping raise the company in terms of the Nasdaq Stock Rating. However, it is important to wait for that exact moment in order to “cross the bridge”.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.